Drug Update · Neurology

Lecanemab: FDA Approves for Alzheimer; CDR‑SB Decline 0.45

July 08, 2026

Primary endpoint (CDR-SB)

Adjusted change 1.21 (lecanemab) vs 1.66 (placebo); difference, -0.45; 95% CI, -0.67 to -0.23; P<0.001 [1]

Amyloid PET substudy

Difference -59.1 centiloids (95% CI, -62.6 to -55.6) favoring lecanemab [1]

Common adverse events

Infusion-related reactions 26.4%; ARIA-E 12.6% in CLARITY AD [1]

Approved starting dose

10 mg/kg IV once every 2 weeks (label) [12][4]

Clinical Perspective

Neurologists and clinicians who manage patients with early Alzheimer’s disease (mild cognitive impairment or mild dementia) now have an FDA‑approved amyloid beta‑directed antibody, lecanemab, for patients with confirmed amyloid pathology ^[5]^[4]. The CLARITY AD data support that lecanemab reduced amyloid plaque burden and resulted in less decline on multiple cognitive and functional measures at 18 months compared with placebo ^[1]^[4]. How clinicians will select patients for treatment, integrate MRI monitoring schedules, and weigh ARIA risk in ApoE ε4 homozygotes remain active practical questions for routine implementation and shared decision making?

Dr. Vikram Patel · Neurology

The U.S. Food and Drug Administration converted Leqembi (lecanemab-irmb) to traditional approval for the treatment of Alzheimer’s disease on July 06, 2023, following confirmatory results from Study 301 (CLARITY AD) showing an 18‑month difference in clinical decline on the Clinical Dementia Rating–Sum of Boxes (CDR‑SB): adjusted least‑squares mean change 1.21 with lecanemab versus 1.66 with placebo (difference, -0.45; 95% CI, -0.67 to -0.23; P<0.001) ^[1]^[4]. The approval and prescribing information recommend initiating treatment in patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease with confirmed amyloid pathology ^[4]^[5].

Clinical Context

Lecanemab is a humanized IgG1 monoclonal antibody directed against aggregated forms of amyloid‑beta soluble protofibrils and is described in the labeling as an amyloid beta‑directed antibody that reduces amyloid plaques in the brain ^[5]. The manufacturer listed in product labeling and prescribing highlights is Eisai Inc.; the pivotal randomized phase 3 trial (Study 301, CLARITY AD) was funded by Eisai and Biogen and formed the basis for conversion to traditional approval ^[1]^[5]. The approved population in labeling is adults with Alzheimer’s disease in the mild cognitive impairment or mild dementia stage of disease, consistent with the enrollment criteria used in the pivotal trials ^[5]. The product label and FDA materials emphasize confirmation of amyloid pathology prior to treatment and MRI monitoring for amyloid‑related imaging abnormalities (ARIA) ^[5]^[4].

Key Findings

The CLARITY AD (Study 301) trial showed lecanemab reduced the change from baseline in the CDR‑SB score at 18 months by 0.45 points versus placebo (adjusted least‑squares mean change 1.21 with lecanemab vs 1.66 with placebo; difference, -0.45; 95% CI, -0.67 to -0.23; P<0.001) ^[1]^[4].
In a substudy of 698 participants, lecanemab produced greater reductions in brain amyloid burden measured by PET (difference, -59.1 centiloids; 95% CI, -62.6 to -55.6) ^[1].
Key secondary clinical differences at 18 months favored lecanemab versus placebo: ADAS‑Cog14 difference, -1.44 (95% CI, -2.27 to -0.61; P<0.001); ADCOMS difference, -0.050 (95% CI, -0.074 to -0.027; P<0.001); and ADCS‑MCI‑ADL difference, 2.0 (95% CI, 1.2 to 2.8; P<0.001) ^[1].
The FDA statement describes these CLARITY AD results as verification of clinical benefit and supported conversion from accelerated to traditional approval; the advisory committee voted that the trial verified clinical benefit ^[4].

Safety & Tolerability

Infusion‑related reactions occurred in 26.4% of participants in CLARITY AD ^[1].
Amyloid‑related imaging abnormalities with edema or effusions (ARIA‑E) occurred in 12.6% of participants in CLARITY AD ^[1].
The prescribing information and Medication Guide list infusion‑related reactions, amyloid related imaging abnormality‑microhemorrhages (ARIA‑H), amyloid related imaging abnormality‑edema/effusion (ARIA‑E), and headache as among the most common adverse reactions (approximately ≥10% and higher incidence versus placebo) ^[2]^[3]^[5].
The FDA press materials and label note that ARIA can be symptomatic and, in this class, has been associated with serious intracerebral hemorrhages in some cases; ApoE ε4 homozygotes have a higher incidence of ARIA ^[4]^[5].

Study Design

Study 301 (CLARITY AD) was an 18‑month, multicenter, double‑blind, randomized, placebo‑controlled, phase 3 trial in participants 50 to 90 years old with early Alzheimer’s disease (mild cognitive impairment or mild dementia) and evidence of amyloid pathology, randomized 1:1 to intravenous lecanemab 10 mg/kg every 2 weeks or placebo ^[1]^[4]. Clinicians should consult current prescribing information for full dosing guidance. A total of 1,795 participants were enrolled (898 assigned to lecanemab and 897 to placebo); primary endpoint was change from baseline at 18 months in the Clinical Dementia Rating‑Sum of Boxes (CDR‑SB) ^[1]. The FDA conversion to traditional approval was based on CLARITY AD demonstrating reduced clinical decline; the FDA convened an advisory committee which voted that the study verified clinical benefit ^[4].

FAQ

Q1 What is lecanemab (Leqembi) approved for?

Leqembi (lecanemab‑irmb) is approved for the treatment of Alzheimer’s disease and treatment should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population studied in the pivotal trials. The FDA converted the drug from accelerated to traditional approval after the CLARITY AD (Study 301) confirmatory trial verified clinical benefit. Prescribers are instructed to confirm the presence of amyloid beta pathology prior to initiating treatment.

Q2 How does lecanemab work?

Lecanemab is a humanized IgG1 monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta, binding with high affinity to soluble protofibrils. Labeling and trial reports state that lecanemab reduces brain amyloid beta plaques as measured by PET and that plaque reduction was accompanied by smaller mean declines on cognitive and functional measures at 18 months in the pivotal trial.

Q3 What is the recommended dose of lecanemab?

The recommended starting dosage in the prescribing information is 10 mg/kg administered as an intravenous infusion once every 2 weeks; after 18 months, options include continuing 10 mg/kg once every 2 weeks or transitioning to a maintenance regimen of intravenous 10 mg/kg once every 4 weeks or subcutaneous 360 mg once weekly using the autoinjector. The label instructs confirmation of amyloid pathology and baseline and interval MRI monitoring for ARIA; dosing details, infusion preparation, and monitoring schedules are in the full prescribing information. Clinicians should consult current prescribing information for complete dosing guidance.

Q4 What are the most common side effects of lecanemab?

The most common adverse reactions reported in clinical trials and prescribing information include infusion‑related reactions, amyloid‑related imaging abnormalities (ARIA) including ARIA‑E (edema/effusion) and ARIA‑H (microhemorrhages), and headache. In CLARITY AD, infusion‑related reactions occurred in 26.4% of participants and ARIA‑E (edema/effusion) occurred in 12.6% of participants. The label emphasizes that ARIA can be asymptomatic but may be symptomatic and serious; ApoE ε4 homozygotes have a higher incidence of ARIA, and MRI monitoring is recommended according to the product labeling.

Clinicians should consult current prescribing information for complete dosing guidance.

Lecanemab: FDA Approves for Alzheimer; CDR‑SB Decline 0.45

Lecanemab: FDA Approves for Alzheimer; CDR‑SB Decline 0.45

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly clinical updates for Neurology in your inbox.

Related Clinical Updates

Smoother Epilepsy Care Transitions

Improve Parkinson's Symptoms with Targeted Therapy

No Efficacy Found in Chronic Stroke Treatment

Verified HCP Portal